| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Division of Hematology/Oncology [T. P. C., N. H. V., Y. Y. M., M. A. C.] and Department of Pathology [M. H. C., J. D. S.], Childrens Hospital Medical Center, Cincinnati, Ohio 45229; Division of Pediatric Hematology/Oncology, University of Wisconsin Childrens Hospital and Comprehensive Cancer Center, Madison, Wisconsin 53792 [E. J. D., A. D. H., A. S.]; University of Alabama, Birmingham, Alabama 35294 [V. K., D. T. C.]; Research and Development, GenVec Inc., Gaithersburg, Maryland 20879 [T. J. W.]; University of Colorado Health Sciences Center, Denver, Colorado 80262 [J. D.]; and Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [J. M. B.]
Exploiting the lytic life cycle of viruses has gained recent attention as an anticancer strategy (oncolysis). To explore the utility of adenovirus (Ad)-mediated oncolysis for rhabdomyosarcoma (RMS), we tested RMS cell lines for Ad gene transduction and infection. RMS cells were variably transduced by Ad. Compared with control cells, RMS cells were less sensitive or even resistant to oncolysis by wild-type virus. RMS cells expressed the Ad internalization receptors,
v integrins, but had low or undetectable expression of the major attachment receptor, coxsackievirus-Ad receptor (CAR). Mutant Ads with ablated CAR binding exhibited only 520% of transgene expression in RMS cells seen with a wild-type vector, suggesting that residual or heterogeneous CAR expression mediated the little transduction that was detectable. Immunohistochemical analysis of archived clinical specimens showed little detectable CAR expression in five embryonal and eight alveolar RMS tumors. Stable transduction of the cDNA for CAR enabled both efficient Ad gene transfer and oncolysis for otherwise resistant RMS cells, suggesting that poor CAR expression is the limiting feature. Gene transfer to RMS cells was increased >2 logs using Ads engineered with modified fiber knobs containing either an integrin-binding RGD peptide or a polylysine peptide in the exposed HI loop. The RGD modification enabled increased oncolysis for RMS cells by a conditionally replicative Ad, Ad
24RGD, harboring a retinoblastoma-binding mutation in the E1A gene. Thus, the development of replication-competent vectors targeted to cell surface receptors other than CAR is critical to advance the use of Ad for treating RMS.
This article has been cited by other articles:
![]() |
H.-J. Li, M. Everts, M. Yamamoto, D. T. Curiel, and H. R. Herschman Combined Transductional Untargeting/Retargeting and Transcriptional Restriction Enhances Adenovirus Gene Targeting and Therapy for Hepatic Colorectal Cancer Tumors Cancer Res., January 15, 2009; 69(2): 554 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.H. Hassan, N. Khatoon, D.T. Curiel, F.M. Hamada, H.M. Arafa, and A. Al-Hendy Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells Hum. Reprod., March 1, 2008; 23(3): 514 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al. A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gomez-Manzano, M. M. Alonso, W.K. A. Yung, F. McCormick, D. T. Curiel, F. F. Lang, H. Jiang, B. N. Bekele, X. Zhou, R. Alemany, et al. Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan Clin. Cancer Res., January 15, 2006; 12(2): 556 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Kuhnel, B. Schulte, T. Wirth, N. Woller, S. Schafers, L. Zender, M. Manns, and S. Kubicka Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating Vectors J. Virol., December 15, 2004; 78(24): 13743 - 13754. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Gu, A. Ogose, H. Kawashima, M. Ito, T. Ito, A. Matsuba, H. Kitahara, T. Hotta, K. Tokunaga, H. Hatano, et al. High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing's Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors Clin. Cancer Res., June 1, 2004; 10(11): 3831 - 3838. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Qin, S. Chen, T. Yu, B. Escuadro, S. Sharma, and R. K. Batra Coxsackievirus Adenovirus Receptor Expression Predicts the Efficiency of Adenoviral Gene Transfer into Non-Small Cell Lung Cancer Xenografts Clin. Cancer Res., October 15, 2003; 9(13): 4992 - 4999. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Hamid, M. L. Varterasian, S. Wadler, J. R. Hecht, A. Benson III, E. Galanis, M. Uprichard, C. Omer, P. Bycott, R. C. Hackman, et al. Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., April 15, 2003; 21(8): 1498 - 1504. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Schoggins, J. G. D. Gall, and E. Falck-Pedersen Subgroup B and F Fiber Chimeras Eliminate Normal Adenovirus Type 5 Vector Transduction In Vitro and In Vivo J. Virol., December 20, 2002; 77(2): 1039 - 1048. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Cancer Res., August 1, 2002; 62(15): 4273 - 4281. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hemminki, K. R. Zinn, B. Liu, T. R. Chaudhuri, R. A. Desmond, B. E. Rogers, M. N. Barnes, R. D. Alvarez, and D. T. Curiel In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus J Natl Cancer Inst, May 15, 2002; 94(10): 741 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. van Beusechem, J. Grill, D. C. J. Mastenbroek, T. J. Wickham, P. W. Roelvink, H. J. Haisma, M. L. M. Lamfers, C. M. F. Dirven, H. M. Pinedo, and W. R. Gerritsen Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished J. Virol., February 22, 2002; 76(6): 2753 - 2762. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kim, T. Smith, N. Idamakanti, K. Mulgrew, M. Kaloss, H. Kylefjord, P. C. Ryan, M. Kaleko, and S. C. Stevenson Targeting Adenoviral Vectors by Using the Extracellular Domain of the Coxsackie-Adenovirus Receptor: Improved Potency via Trimerization J. Virol., February 15, 2002; 76(4): 1892 - 1903. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |